Highest Analyst Upside Stocks
RGEN is part of our highest analyst upside stock list, indicating analysts have a price target way above the current price.
REPLIGEN CORP (RGEN) Stock Price & Overview
NASDAQ:RGEN • US7599161095
Current stock price
132.93 USD
+5.84 (+4.6%)
Last:
The current stock price of RGEN is 132.93 USD. Today RGEN is up by 4.6%. In the past month the price increased by 8.08%. In the past year, price decreased by -2.24%.
RGEN Key Statistics
52-Week Range109.66 - 175.77
Current RGEN stock price positioned within its 52-week range.
1-Month Range109.66 - 133.55
Current RGEN stock price positioned within its 1-month range.
- Market Cap
- 7.497B
- P/E
- 77.74
- Fwd P/E
- 66.37
- EPS (TTM)
- 1.71
- Dividend Yield
- N/A
RGEN Stock Performance
Today
+4.6%
1 Week
+6.10%
1 Month
+8.08%
3 Months
-21.56%
Longer-term
6 Months -16.72%
1 Year -2.24%
2 Years -22.60%
3 Years -16.18%
5 Years -39.97%
10 Years +377.07%
RGEN Stock Chart
RGEN Stock Screens
RGEN currently appears in the following ChartMill screener lists.
RGEN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RGEN. When comparing the yearly performance of all stocks, RGEN is a bad performer in the overall market: 82.38% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
RGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to RGEN. While RGEN has a great health rating, its profitability is only average at the moment.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RGEN Earnings
On February 24, 2026 RGEN reported an EPS of 0.49 and a revenue of 197.91M. The company beat EPS expectations (9.25% surprise) and beat revenue expectations (0.58% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported$0.49
Revenue Reported197.913M
EPS Surprise 9.25%
Revenue Surprise 0.58%
RGEN Forecast & Estimates
28 analysts have analysed RGEN and the average price target is 191.89 USD. This implies a price increase of 44.35% is expected in the next year compared to the current price of 132.93.
For the next year, analysts expect an EPS growth of 17.13% and a revenue growth 12.85% for RGEN
Analysts
Analysts81.43
Price Target191.89 (44.35%)
EPS Next Y17.13%
Revenue Next Year12.85%
RGEN Groups
Sector & Classification
RGEN Financial Highlights
Over the last trailing twelve months RGEN reported a non-GAAP Earnings per Share(EPS) of 1.71. The EPS increased by 15.54% compared to the year before.
Income Statements
Revenue(TTM)738.26M
Net Income(TTM)48.89M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.62% | ||
| ROA | 1.66% | ||
| ROE | 2.32% | ||
| Debt/Equity | 0.26 |
Chartmill High Growth Momentum
EPS Q2Q%11.36%
Sales Q2Q%18.12%
EPS 1Y (TTM)15.54%
Revenue 1Y (TTM)-6.05%
RGEN Ownership
Ownership
Inst Owners112.24%
Shares56.40M
Float53.10M
Ins Owners0.32%
Short Float %10.46%
Short Ratio6.28
RGEN Competitors/Peers
The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 21.37 | 191.684B | ||
| DHR | DANAHER CORP | 23.09 | 137.138B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 145.2 | 46.589B | ||
| A | AGILENT TECHNOLOGIES INC | 18.03 | 33.417B | ||
| WAT | WATERS CORP | 22.56 | 31.298B | ||
| IQV | IQVIA HOLDINGS INC | 13.89 | 28.865B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 28.43 | 26.14B | ||
| ILMN | ILLUMINA INC | 25.43 | 20.293B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 33.62 | 19.448B | ||
| MEDP | MEDPACE HOLDINGS INC | 29.7 | 14.727B | ||
| RVTY | REVVITY INC | 16.96 | 10.01B | ||
| TEM | TEMPUS AI INC-CL A | N/A | 9.729B | ||
| TECH | BIO-TECHNE CORP | 26.78 | 8.974B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RGEN
Company Profile
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 2,000 full-time employees. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Company Info
IPO: 1986-04-29
REPLIGEN CORP
Building 1, Suite 100, 41 Seyon Street
Waltham MASSACHUSETTS 02453 US
CEO: Tony J. Hunt
Employees: 2000
Phone: 17814499560
REPLIGEN CORP / RGEN FAQ
Can you describe the business of REPLIGEN CORP?
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 2,000 full-time employees. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
What is the current price of RGEN stock?
The current stock price of RGEN is 132.93 USD. The price increased by 4.6% in the last trading session.
Does REPLIGEN CORP pay dividends?
RGEN does not pay a dividend.
What is the ChartMill rating of REPLIGEN CORP stock?
RGEN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the growth outlook for REPLIGEN CORP?
The Revenue of REPLIGEN CORP (RGEN) is expected to grow by 12.85% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for RGEN stock?
REPLIGEN CORP (RGEN) currently has 2000 employees.
What is REPLIGEN CORP worth?
REPLIGEN CORP (RGEN) has a market capitalization of 7.50B USD. This makes RGEN a Mid Cap stock.